Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GPCR vs GRAL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GRAL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

GRAL Overall Winner 6-Pillar Tally: GPCR 2 – 3 GRAL (1 Tie) Matrix Metrics: GPCR 3 – 7 GRAL

As of Nov 16, 2026, GRAIL, Inc. (GRAL) is the stronger overall head-to-head candidate over Structure Therapeutics Inc. (GPCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GPCR carries a Unified Composite Score of 41.2/100 (SELL) at $18.57 (N/M Forward P/E, 0.0% operating margin), whereas GRAL carries 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin).

  • Technical & Structure Timing Caution: GPCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GPCR vs GRAL
GPCR NASDAQ
Structure Therapeutics Inc. American Depositary Shares
Pharmaceutical Preparations
$18.57
-7.15% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.37β · 58% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.2%), weak momentum, RSI 28
RSI-14: 28.4 · SMA20: $20.95 · SMA50: $27.31
GRAL NASDAQ Head-to-Head Winner
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37

6-Pillar Scorecard Institutional Category Breakdown (GPCR 2 – 3 GRAL)

Columns: Metric · GPCR · GRAL
1. Valuation Multiples GRAL
Forward P/E N/M 1.1x
Trailing P/E N/M 1.1x
PEG Ratio N/M N/M
EV / Revenue N/M 31.6x
2. Growth & Scale GRAL
Revenue Growth (YoY) +0.0% +3.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $167M
Market Cap $1.4B $5.2B
3. Profitability & Quality GPCR
Gross Margin N/A 46.7%
Operating Margin 0.0% -332.0%
Net Profit Margin 0.0% -243.8%
Return on Equity (ROE) -20.2% -17.3%
4. Balance Sheet & Cash Flow GRAL
Cash Generation (TTM) N/A -$312M
Cash Flow Margin N/A N/A
Net Cash / Leverage $21.41 Book/Sh · -20.2% ROE $57M Net Debt (0.03x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning GPCR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 120.4% (<1st %ile) 93.0% (53rd %ile)
Put/Call OI Skew Thin ADR Chain 0.81x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GPCR (3) vs GRAL (7)
Institutional Metric GPCR GRAL Criterion Row Edge
Market Capitalization
Scale
$1.4B $5.2B Larger Scale GRAL
Trailing P/E Ratio
Valuation
N/M 1.1x Lower Multiple GRAL
Forward P/E Ratio
Valuation
N/M 1.1x Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+0.0% +3.7% Higher Growth GRAL
Operating Margin (TTM)
Profitability
0.0% -332.0% Higher Margin GPCR
Net Profit Margin
Profitability
0.0% -243.8% Higher Margin GPCR
Return on Equity (ROE)
Capital Efficiency
-20.2% -17.3% Higher ROE GRAL
52-Week Range Position
Momentum
0% ($18–$95) 51% ($42–$166) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
1.37β · 58% Vol 3.09β · 99% Vol Lower Realized Risk GPCR
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 54.5 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
N/A $167M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 46.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 31.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($21.41 Book/Sh · -20.2% ROE) -$312M ($57M Net Debt (0.03x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +1.55 pp
GPCR: -11.91% · GRAL: -10.36%
3M Horizon GRAL +116.42 pp
GPCR: -65.46% · GRAL: +50.96%
6M Horizon GRAL +129.03 pp
GPCR: -52.0% · GRAL: +77.03%
1Y Horizon GRAL +73.86 pp
GPCR: -46.94% · GRAL: +26.92%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GPCR vs GRAL. Trailing 12-month operating profitability (GPCR 0.0% vs GRAL -332.0%) and valuation multiples (GPCR N/M vs GRAL 1.1x Forward P/E) are benchmarked directly in Pillar 4 below.

GPCR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-20.2% · N/M
GRAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$167M
Gross Margin46.7%
Op. Margin-332.0%
ROE / Fwd P/E-17.3% · 1.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GPCR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 120.4%
IV Percentile <1st %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GPCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GPCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GPCR vs GRAL Key Questions & Quantitative Answers

As of Nov 16, 2026, GRAIL, Inc. (GRAL) is the stronger overall head-to-head candidate over Structure Therapeutics Inc. (GPCR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). GPCR carries a Unified Composite Score of 41.2/100 (SELL) at $18.57 (N/M Forward P/E, 0.0% operating margin), whereas GRAL carries 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin). Technical & Structure Timing Caution: GPCR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.4); meanwhile GRAL is in a Breakdown options structure phase (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

GRAL leads the Growth & Scale pillar: GPCR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GRAL at +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin). On trailing 12-month operating scale, GPCR generates N/A in USD-normalized revenue versus $167M for GRAL. In operating R&D and SG&A reinvestment, GPCR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRAL.

GRAL screens cheaper on headline valuation multiples. GPCR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GPCR (-20.2% ROE) versus GRAL (-17.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GPCR carries 120.4% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.37β · 58% Vol realized risk). By comparison, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.